102676-87-9

Basic information

• Product Name: Benzonitrile, 4-[(5R)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl]-
• CAS NO: 102676-87-9
• Molecular Formula: C14H13N3
• Molecular Weight: 223.277
• Mol File: 102676-87-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzonitrile, 4-[(5R)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzonitrile, 4-[(5R)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl]-(102676-87-9)
• EPA Substance Registry System: Benzonitrile, 4-[(5R)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl]-(102676-87-9)

Safety Data

• Hazardous Substances Data: 102676-87-9(Hazardous Substances Data)

Upstream product

• 102676-47-1 fadrozole 
• 93178-73-5 5-(4-carboxyphenyl)-5,6,7,8-tetrahydroimidazo<1,5-a>pyridine 
• 93178-72-4 5-<4-(ethoxycarbonyl)phenyl>-5,6,7,8-tetrahydroimidazo<1,5-a>pyridine hydrochloride 
• 102676-41-5 2-<4-(ethoxycarbonyl)phenyl>-6-<(formylamino)methyl>pyridine 
• 93178-58-6 5-(p-ethoxycarbonylphenyl)-imidazo[1,5-a]pyridine 
• 102676-39-1 6-cyano-2-<4-(ethoxycarbonyl)phenyl>pyridine 
• 102676-40-4 6-(aminomethyl)-2-<4-(ethoxycarbonyl)phenyl>pyridine 
• 102676-38-0 2-<4-(ethoxycarbonyl)phenyl>pyridine N-oxide 
• 4385-61-9 ethyl 4-(2-pyridinyl)benzoate 
• 102676-30-2 5-(3-chloropropyl)-1-<(4-cyanophenyl)methyl>-1H-imidazole 
• 102676-43-7 5-(4-carbamylphenyl)-5,6,7,8-tetrahydroimidazo<1,5-a>pyridine 

Relevant articles and documents

R-FADROZOLE FOR USE IN THE TREATMENT OF ALDOSTONERISM

The present invention relates to a composition for use in the treatment of a disease or disorder, wherein said disease or disorder is preferably a disease or disorder in which aldosterone overexposure contributes to the symptoms of said disease or disorder, said composition comprises a compound which is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8- tetrahydroimidazo[1,5-a]pyridine or a pharmaceutically acceptable salt thereof, wherein preferably said compound is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[1,5- a]pyridine dihydrogen phosphate, and wherein said compound has an enantiomeric excess (ee) of the (R) form higher than or equal to 97%, and wherein said composition is administered once daily to a subject in need thereof. The invention further relates to a pharmaceutical composition comprising a daily dosage of said compound in a fixed-unit dosage form and to a combination comprising (i) said pharmaceutical composition or said compound; and (ii) instructions for administration of said pharmaceutical composition or said compound once per day.

Aromatase inhibitors: Synthesis, biological activity, and binding mode of azole-type compounds

The enantiomers of the potent nonsteroidal inhibitor of aromatase fadrozole hydrochloride 3 have been separated and their absolute configuration determined by X-ray crystallography. On the basis of a molecular modeling comparison of the active enantiomer